Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the cardiovascular treatment sector, addressing an unmet clinical need for emergency hypertension medications [1] Company Summary - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug, suitable for patients who cannot take oral medications or have poor expected responses to oral treatments [1] - The injection comes in two formulations: 50ml with 25mg and 100ml with 50mg [1] - The approval enhances the company's product pipeline in the cardiovascular disease treatment area, increasing its competitiveness in this field [1] Product Advantages - The product offers significant advantages over commonly used clinical medications, including faster onset of action, allowing for rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which can significantly benefit patients at risk of fluid overload [1] Market Implications - The approval is expected to fill a clinical demand gap for emergency hypertension medications, thereby potentially increasing market share and revenue for the company in the cardiovascular sector [1]
石药集团(01093)：氯维地平乳状注射液获药品注册批件